SCARA5 and DIO2 as biomarkers for miscarriage and implantation failure
AssigneeUniversity of Warwick
InventorJan Brosens
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for assessing the risk of miscarriage or embryo implantation failure, and also for monitoring or evaluating the effect of a treatment to reduce the risk of miscarriage or embryo implantation failure using specific biomarkers. The invention also relates to the use of these biomarkers in methods of diagnosing a reproductive disorder in an individual, and also to methods of treating a reproductive disorder. In addition, the biomarkers can further be used in methods of selecting patients for treatment to reduce risk of embryo implantation failure or miscarriage. The invention also relates to kits for use in any of the methods described herein.
Claims12
A method of treating a reproductive disorder in a female individual, the method comprising
- administering an agent to, and/or carrying out a treatment regimen on, the individual who is positively diagnosed or assessed as being at risk of a reproductive disorder, to treat the reproductive disorder;
- wherein the individual is positively diagnosed or assessed as being at risk of a reproductive disorder, by having an increased level of DIO2, and/or by having a decreased level of SCARA5 as compared with a reference sample or level which represents the sample or the level from an individual or multiple individuals known to not have any reproductive disorder;
- wherein the agent is a dipeptidyl-peptidase IV (DPP4) inhibitor;
- wherein the treatment regimen comprises endometrial scratching;
- and
- wherein administration of the agent to or carrying out the treatment regimen on the individual is prior to pregnancy.
A method of treating a reproductive disorder in a female individual, the method comprising
- diagnosing the reproductive disorder, wherein the individual is positively diagnosed or assessed as being at risk of a reproductive disorder by having an increased level of DIO2 and by having a decreased level of SCARA5 as compared with a reference sample or level which represents the sample or the level from an individual or multiple individuals known to have to not have any reproductive disorder;
- administering an agent and/or carrying out a treatment regimen effective to the individual who is positively diagnosed or assessed as being at risk of a reproductive disorder, to treat the reproductive disorder;
- wherein the agent is a dipeptidyl-peptidase IV (DPP4) inhibitor;
- wherein the treatment regimen involves endometrial scratching;
- and
- wherein administration of the agent to or carrying out the treatment regimen on the individual is prior to pregnancy.
Dependencies are inferred from the claim text.